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Abstract
Background: Bacille Calmette-Guerin (BCG) is currently the only available vaccine against tuberculosis (TB) and
comprises a heterogeneous family of sub-strains with genotypic and phenotypic differences. The World Health
Organization (WHO) affirms that the characterization of BCG sub-strains, both on genomic and proteomic levels, is
crucial for a better comprehension of the vaccine. In addition, these studies can contribute in the development of
a more efficient vaccine against TB. Here, we combine two-dimensional electrophoresis (2DE) and mass
spectrometry to analyse the proteomic profile of culture filtrate proteins (CFPs) from M. bovis BCG Moreau, the
Brazilian vaccine strain, comparing it to that of BCG Pasteur. CFPs are considered of great importance given their
dominant immunogenicity and role in pathogenesis, being available for interaction with host cells since early
infection.
Results: The 2DE proteomic map of M. bovis BCG Moreau CFPs in the pH range 3 - 8 allowed the identification of
158 spots corresponding to 101 different proteins, identified by MS/MS. Comparison to BCG Pasteur highlights the
great similarity between these BCG strains. However, quantitative analysis shows a higher expression of
immunogenic proteins such as Rv1860 (BCG1896, Apa), Rv1926c (BCG1965c, Mpb63) and Rv1886c (BCG1923c,
Ag85B) in BCG Moreau when compared to BCG Pasteur, while some heat shock proteins, such as Rv0440
(BCG0479, GroEL2) and Rv0350 (BCG0389, DnaK), show the opposite pattern.
Conclusions: Here we report the detailed 2DE profile of CFPs from M. bovis BCG Moreau and its comparison to
BCG Pasteur, identifying differences that may provide relevant information on vaccine efficacy. These findings
contribute to the detailed characterization of the Brazilian vaccine strain against TB, revealing aspects that may lead
to a better understanding of the factors leading to BCG’s variable protective efficacy against TB.
Background
Tuberculosis (TB) remains a major cause of morbidity
and mortality, particularly in developing countries, and
is considered a serious public health problem world-
wide, killing almost 2 million people every year [1].
According to the WHO, one-third of the world’s popu-
lation is infected with Mycobacterium tuberculosis
(Mtb). The incidence of new cases of TB has increased
mainly due to the impact of the HIV epidemic [2] and
the emergence of resistance to anti-TB drugs [3]. The
currently available vaccine, Mycobacterium bovis bacil-
lus Calmette-Guérin (BCG), is one of the oldest and
most commonly administered vaccines worldwide [4].
It was obtained in the early 1920’s by Albert Calmette
and Camille Guérin at the Pasteur Institute, Lille,
France, after 231 serial passages of a clinical isolate of
M. bovis in glycerinated medium containing ox bile
[5]. Attenuation during in vitro passages is believed to
have resulted from the loss and/or reorganization of
genomic regions, some of which have been recently
identified [6-9]. M. bovis BCG Moreau is the strain
used in Brazil for vaccine production since the 1930’s
[10]. According to recent molecular studies [11], it is
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considered an “old” strain, more similar to the original
BCG derived by Calmette and Guérin. Vaccination
with BCG has many advantages, yielding efficient pro-
tection against severe childhood forms of TB, and also
against leprosy [12]. In addition, it is recognized as a
safe and inexpensive vaccine that can be administered
shortly after birth [13,14]. On the other hand, it shows
variable protection against the most common form of
the disease, pulmonary tuberculosis in adults, and it
does not prevent the establishment of latent TB. It has
been reported that different M. bovis BCG strains,
including BCG Moreau, induce varying levels of pro-
tection against M. tuberculosis infection in animal
models [15]. Comparative genetic analysis of BCG
strains has revealed that each vaccine currently in use
is unique [11], and providing several clues for the fail-
ure of BCG as an effective vaccine. Proteomic studies
have shown that BCG strains with similar genomic
content, such as BCG Denmark and Phipps, exhibit
phenotypic differences that can be particularly impor-
tant for pathogenesis, immune response and variable
efficacy of BCG vaccine [16]. Other factors have also
been implicated in its unpredictable efficacy: (i) the
genetic variability amongst vaccinated individuals; (ii)
cross-reactivity of the immune response to BCG due
to environmental mycobacteria [17]; (iii) differences in
vaccine production procedures, variable doses, and
bacterial viability, amongst others [18,19]. New vacci-
nation strategies are therefore urgently needed, parti-
cularly against pulmonary forms of TB.
The modulation of cellular functions of the host cell is
a dynamic process that requires viable mycobacteria,
supporting the idea that the components actively
secreted by the living bacteria are the main players
involved in this process [20]. Membrane and membrane
associated proteins also play an important role in this
process [21]. Subunit vaccines based on mixtures of cul-
ture filtrate proteins have resulted in protective immu-
nity in animal models of TB [22-26]. These molecules
are also strongly recognized during Mtb infection in var-
ious animal models, as well as in early stages of pulmon-
ary TB in humans [27,28]. Culture filtrate is therefore an
attractive source of potential candidate antigens for the
development of new vaccines and diagnostic reagents. In
this report, we have employed a combination of 2DE
and mass spectrometry analysis in order to generate a
proteomic map of CFPs from the Brazilian M. bovis
BCG Moreau strain, comparing it to the reference
strain, M. bovis BCG Pasteur. The data presented may
contribute to the identification of useful markers for
quality control of the BCG Moreau vaccine production,
and yield possible clues regarding the variable effective-
ness of these vaccine strains.
Results
Protein separation, identification and sub-cellular
localization
The BCG strains were grown in static cultures, as sur-
face pellicles, for 15 days, with no apparent difference
in growth. The genetic profile of the 2 strains was con-
firmed by PCR (Additional file 1, Figure S1), corroborat-
ing with previous reports [29] The preliminary
separation of BCG Moreau CFPs by 2DE revealed that
most protein spots clustered in the pH range 3-8 (data
not shown). To generate proteomic maps, samples were
therefore applied to immobilized pH gradient (IPG)
strips in the pH intervals 3-6 (Figure 1A and 1C) and
5-8 (Figure 1B and 1D) and subsequently separated in
the second dimension across 12% (Figure 1A and 1B)
and 15% SDS-PAGE (Figure 1C and 1D). To aid in
visualization, gel images were merged to produce an
artificial map representative of the pH range 3-8 (Figure
1E) comprising all the 280 spots resolved in the indivi-
dual gels. These spots were excised and digested with
trypsin. The resulting peptides were submitted to mass
spectrometry analysis leading to the putative identifica-
tion of 158 protein spots corresponding to 101 different
proteins (Additional file 2, Table S1). For clarity, we
have adopted the standard protein nomenclature used
for M. tuberculosis strain H37Rv (http://genolist.pasteur.
fr/tuberculist) and M. bovis BCG Pasteur 1173P2
(http://genolist.pasteur.fr/BCGList/). Identified proteins
showed a pI variation between 3-8 and a molecular
mass (Mr) range between 9 and 120 kDa. The compari-
son of experimentally determined and theoretical Mr
and pI values of the identified protein spots from BCG
Moreau against the predicted values for M. tuberculosis
strain H37Rv proteins, obtained from the search with
Mascot version 2.2, showed a positive correlation
according to the Spearman coefficient (Figure 2A and
2B) Considering the fact that the proteins identified in
this study were obtained from the culture filtrate, we
analyzed the presence of possible signals that could
direct these proteins to the extracellular fraction (Addi-
tional file 3, Table S2), using Signal P (for sec-depen-
dent secretion; [30]), LipoP (lipoproteins; [31]), TatP
(for secretion through the twin-arginine translocation
system; [32]) and SecretomeP (for non-classical secre-
tion of leaderless proteins; [33]). Of the 101 proteins, 67
(66%) have no extracellular prediction. However, when
we compare our data to 2 previous reports on the cul-
ture filtrate proteome of M. tuberculosis H37Rv - the
2DE database at the Max Planck Institute (http://web.
mpiib-berlin.mpg.de/) and a recent work by de Souza
and collaborators [34] - 93 proteins (92%) have been
previously reported in one or both studies, including 60
of the proteins with no extracellular prediction. We also
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evaluated the number of potential transmembrane (TM)
domains using TMHMM ([35]; Additional file 3, Table
S2). Thirteen proteins were found to contain 1 pre-
dicted TM domain which, although coinciding in all
cases with the signal peptide region predicted by Sig-
nalP, does not exclude a possible membrane localization
for some of these proteins [36]. For the 22 proteins
with a predicted signal peptide, the theoretical pI
and Mr were calculated for the full protein and for
the mature protein, after removal of the signal
peptide region predicted by SignalP (Additional file 4,
Table S3).
Figure 1 2DE proteomic profile of CFPs from M. bovis BCG Moreau. Proteins (500 ug) were applied to 17 cm IPG strips in the pH intervals
of 3 - 6 (panels A and C) and 5 - 8 (panels B and D) and separated in the second dimension across 12% (panels A and B) and 15% (panels C
and D) SDS-PAGE. The images were merged to obtain a composite map in the pH range 3 - 8 (panel E). Protein spots were visualized by
colloidal CBB-G250 staining. Identified proteins are numbered in panel E and detailed in Additional file 2, Table S1. Molecular weight standards
indicated in kDa.
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Predicted biological functions for the identified proteins
The assignment of the identified CFPs into functional
categories was based on the functional classification tree
from BCGList (http://genolist.pasteur.fr/BCGList/). The
101 proteins identified by MS/MS are distributed across
7 of those functional groups (Figure 3). The largest
groups were “intermediary metabolism and respiration”
(35%), “cell wall and cell processes” (23%) and “con-
served hypotheticals” (17%).
Differential CFP proteomic profiles between M. bovis BCG
strains Moreau and Pasteur
The 2DE profiles from M. bovis BCG strains Moreau
and Pasteur were compared to identify differences that
could provide relevant information about the Brazilian
vaccine strain. For quantification analyses of the protein
spots derived from both strains, the PDQuest software
was used, comparing the optical densities of the
matched spots in 2DE gel images. The experiments
were repeated at least 3 times, and only the differences
confirmed in all comparisons were accepted as strain
specific. As expected, the proteomic profiles of CFPs
from BCG strains Moreau and Pasteur were very similar
(Figure 4 A-D); however, some variations in relative pro-
tein quantifications were observed. A total of 9 proteins
represented by 18 spots showed a differential expression
pattern between the two BCG strains (Table 1, Figure 5
and Additional file 5, Figure S2). In addition, 2 proteins
were found exclusively in BCG Moreau and one protein
exclusively in BCG Pasteur (Figure 4 A-D and Addi-
tional file 6, Figure S3).
Quantitative analysis revealed that 5 proteins were
present in at least 2-fold higher concentration in BCG
Moreau when compared to BCG Pasteur (Additional file
5, Figure S2): the Apa glycoprotein (Rv1860/BCG1896;
spots 11, 12, 13 and 14); the immunogenic protein
MPB63 (Rv1926c/BCG1965c; spots 109,111, 112 and
160); the secreted antigen 85B (Ag85B, FbpB, Rv1886c/
BCG1923c; spot 58); and proteins MPB70 and MPB83
(Rv2875/BCG2897 and Rv2873/BCG2985; spots 94 and
95, respectively) (Table 1 and Figure 5). Spot 93 was
also identified as MPB70 but was observed only in BCG
Moreau (Figure 4).
Four proteins were more expressed in BCG Pasteur
when compared to Moreau (Additional file 5, Figure
S2): the heat shock proteins Hsp70 (DnaK, Rv0350/
BCG0389; spot 4) and Hsp65 (GroEL2, Cpn60.2,
Rv0440/BCG0479; spot 5); the presumed trigger factor
(Tig, Rv2462c/BCG2482c; spot 7) and the probable
iron-regulated peptidyl-prolyl cis-trans isomerase A
(PPIaseA, Rv0009/BCG0009; spots 89, 90, 91 and 92)
(Table 1 and Figure 5).
As expected, MPB64 (Rv1980c, spots 69 and 158) and
CFP21 (Rv1984c; spot 96) were identified in BCG
Figure 2 Correlation between experimentally determined and theoretical pI and Mr and distribution of predicted cellular localization
of the identified proteins. The experimental and theoretical pI (panel A) and Mr (panel B) values for the identified protein were compared.
Overall, a positive Spearman correlation coefficient r = 0.75, p < 0.0001 and r = 0.95, p < 0.0001, is observed for the data in the pI range
between 3 and 8 and Mr range of 9 to 120 kDa, respectively.
Figure 3 Functional classification of the identified M. bovis BCG
Moreau CFPs. Identified proteins were classified into functional
categories according to BCGList (http://genolist.pasteur.fr/BCGList/).
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Table 1 CFPs differentially expressed between BCG strains Moreau and Pasteur
Spot number Mtb ortholog BCG Pasteur ortholog Protein Ratio# Fold Increase## ± SD p-value
11### Rv1860 BCG1896 Apa M/P 2.31 ± 0.22 0.09
12### M/P 2.01 ± 0.71 0.27
13 M/P 3.42 ± 1.06 0.02
14 M/P 3.05 ± 0.11 0.009
95 Rv2875 BCG2897 Mpt70 M/P 39.50 ± 4.52 0.0004
94 Rv2875/Rv2873 BCG2897/BCG2895 Mpt70/Mpt83 M/P 185.27 ± 30.35 0.004
109### BCG1965c M/P 4.45 ± 1.59 0.19
111 M/P 2.54 ± 0.39 0.03
112### Rv1926c Mpt63 M/P 3.50 ± 0.48 0.41
160 M/P 3.68 ± 0.23 0.03
58 Rv1886c BCG1923c FbpB M/P 2.46 ± 0.034 0.01
7 Rv2462c BCG2482c Tig P/M 3.42 ± 0.13 0.001
89### BCG0009 P/M 2.81 ± 1.24 0.07
90 Rv0009 PPIase A P/M 2.01 ± 0.87 0.008
91 P/M 23.28 ± 0.87 0.005
92 P/M 55.21 ± 12.61 0.05
4 Rv0350 BCG0389 DnaK P/M 2.04 ± 0.21 0.03
5 Rv0440 BCG0479 GroEL2 P/M 15.66 ± 0.93 0.00005
#In order to report values as fold increase, ratio was calculated for BCG Moreau (M) in relation to Pasteur (P) or vice-versa, as specified
##Ratio of mean pixel intensity value (±SD) for the specified protein spot in one BCG strain vs. the other
###Protein spots that did not show statistically significant change (p > 0.05)
Figure 4 Comparative 2DE profiles of CFPs from M. bovis BCG strains Moreau and Pasteur. Proteins (500 ug) were applied to IPG strips in
the pH intervals of 3 - 6 (panels A and B) and 4 - 7 (panels C and D) and separated in the second dimension in 12% (panels A and B) and 15%
(panels C and D) SDS-PAGE. Protein spots were visualized by colloidal CBB-G250 staining and the gels images compared with PDQuest (Bio-Rad).
Molecular weight standards indicated in kDa. The sectors shown in more detail in Additional files 5 and 6, Figures S2 and S3, are indicated in
the figure (sectors A - G).
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Moreau but were not present in BCG Pasteur (Figure 4
and Additional file 6, Figure S3) due to the loss of geno-
mic region RD2 in the more recent BCG strains [7]. On
the other hand, BCG Moreau contains a genomic dele-
tion (RD16) encompassing genes rv3400-rv3405c
(bcg3470-bcg3475c). In this study we identified only one
protein present in BCG Pasteur and absent in BCG
Moreau: a probable hydrolase encoded by rv3400
(bcg3470) (Figure 4 and Additional file 6, Figure S3).
This difference is consistent with previous reports [7].
Discussion
The main goal of this study was to perform a compre-
hensive proteomic analysis of CFPs from M. bovis BCG
strains Moreau and Pasteur by combining 2DE and
mass spectrometry, allowing for the evaluation of phe-
notypic differences between the two strains. The 2DE
patterns were highly similar, presenting numerous pro-
minent common spots that could be used as landmarks.
From 2DE gels of CFP preparations from M. bovis BCG
Moreau, 158 spots were identified. The Mr and pI values
estimated by 2DE showed a good correlation with
expected values; however 34% of the identified proteins
were detected in 2 or more spots with different Mr and/
or pI. This is probably due to post-translational modifi-
cations (PTMs) such as glycosylation, phosphorylation
or other modifications already described for several of
the identified proteins [37-40]. For example, Rv1827
(BCG1862, Cfp17, GarA; spots 80, 81, 82) and Rv0020c
(BCG0050c, TB39.8. FhaA; spots 8, 9 and 10) possess
FHA domains that bind phosphothreonine [40], and
Rv0685 (BCG0734, Tuf; spots 28, 29, 30 and 31) is also
described as being phosphorylated in the same amino
acid residues [38].
Protein modifications in prokaryotes are of great bio-
logical interest but are not yet well understood. In this
work we observed several deaminated proteins (approxi-
mately 22%), possibly associated with important biologi-
cal processes such as protein turnover, molecular aging
and cell adhesion [41]. In addition, deamination may be
useful for the refinement of protein searches by MS/MS
as well as tryptophan oxidation and N-terminal pyroglu-
tamylation [42], which are also observed in several pep-
tides identified in this study (Additional file 2, Table
S1). Interestingly, formylation was only observed for one
N-terminal methionine residue in Rv1827 (BCG1862,
Cfp17, GarA), a FHA domain-containing protein that
constitutes the major substrate for an essential kinase,
PknB, in Mtb cell extracts [43]. Formylated peptides and
proteins are specific signatures of bacterial metabolism,
and attractive targets to the innate immune system, ser-
ving as potent chemoattractants for mammalian phago-
cytic leukocytes [44]. The lack of other proteins showing
this particular PTM could also indicate that peptide
deformylases are operating with high efficiency. Another
chemical modification observed was threonine acetyla-
tion. Although N-terminal acetylation is common in
eukaryotic proteins, it has been reported to be rare in
prokaryotes [45]. This PTM is present in 2 proteins
identified as putative ESAT-6 like proteins, EsxI
(Rv1037c, BCG1095c) and EsxN (Rv1793, BCG1825)
(Additional file 2, Table S1). The N-terminal acetylation
may not always alter function, but in Mtb it has been
shown that antigen ESAT-6, which normally interacts
with the protein CFP-10, fails to do so when acetylated
[46], possibly hindering its secretion via the mycobacter-
ial-specific type VII secretion system [47].
In the current study, only 21 (21%) of the identified
proteins were found to have a predicted signal peptide.
Of these, 13 have one predicted TM segment coinciding
with the predicted signal peptide region. Since current
methods are not fully efficient in predicting membrane
retention of proteins with typical Sec-type signal pep-
tides [36], we cannot discard the possibility that the
extracellular localization of some of these proteins may
result from the gradual proteolytic release of membrane
proteins containing a single amino-terminal membrane
anchor.
Several mycobacterial proteins that do not present a
canonical signal peptide can be secreted by alternative
secretion mechanisms, such as the twin-arginine translo-
cation system, the alternative SecA2 pathway or the
Figure 5 CFPs differentially expressed between BCG strains
Moreau and Pasteur. Bars represent fold increase (mean ± SD of
the pixel intensity ratios for each specified protein spot between
strains). Protein spots more expressed in BCG Moreau compared to
Pasteur are represented by blue bars while those more expressed in
BCG Pasteur compared to Moreau are represented by red bars.
Individual values are detailed in Table 1.
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recently described Type VII (Esx) secretion system
[48-50]. Other studies on the culture filtrate proteome
of mycobacteria have also reported the presence of
numerous leaderless proteins [51-53]. Some of the pro-
teins identified by us are also reported in the membrane
proteome of BCG Moreau [54] and the cell wall pro-
teome of M. smegmatis [55]. The abundance in the cul-
ture filtrate of M. bovis BCG Moreau of proteins
without signal peptide prediction may also result from
bacterial lysis, in combination with high levels of protein
expression and extracellular stability, as described for
several Mtb proteins [56]. Nevertheless, the precise
mechanism by which these proteins are exported is still
unknown.
Approximately 24% of the CFPs identified in the pre-
sent study have no defined function (conserved hypothe-
ticals); among these we can highlight the conserved
hypothetical proteins TB27.3 (Rv0577, BCG0622),
TB18.6 (Rv2140c, BCG2175c), Rv2626c (BCG2653c) and
TB15.3 (Rv1636, BCG1674) this last, recently described
as being differentially expressed in the secretome of a
recombinant BCG strain [57]. Although their functions
have not been established, these proteins have been con-
sidered as antigens, able to distinguish between tubercu-
losis clinical states, or attractive targets for the
development of new drugs, vaccines and diagnostic stra-
tegies for TB [58-60].
Several other mycobacterial antigens, previously
described as important for vaccine development and TB
diagnosis, have also been identified in the present study,
including the ESAT-6 like protein EsxG (Rv0287,
BCG0327), recognized by multiple T-cell lines and able
to boost IFN-g levels in mouse and guinea pig models
of TB [61], and the secreted MPT51 protein (Rv3803c,
BCG3865c), described as being able to induce higher
levels of antigen-specific CD8+ T-cell responses [62].
Proteins involved in biosynthesis and degradation of
fatty acids were also identified, such as the members of
the antigen-85 complex, FbpA (Rv3804c, BCG3866c),
FbpB (Rv1886c, BCG1923c), FbpC (Rv0129c,
BCG0163) and FbpD (Rv3803c, BCG3865c; Mpb51),
essential for the biosynthesis of mycolic acids [63]. In
this work, Ag85B (FbpB) was found to be more abun-
dant in the culture filtrate of BCG Moreau than in
that of BCG Pasteur. The protein has been shown to
induce partial protection against TB in animal models,
and is considered an important immunodominant anti-
gen and a promising vaccine candidate [64]. MPT64
(Rv1980) and CFP21 (Rv1984c) were found only in
BCG Moreau; both are described in the literature as
immunogenic antigens and potential targets for the
development of new vaccines against TB [65,66]. The
genes encoding these proteins are located in RD2, a
genomic region deleted in a number of more recent
BCG strains, including M. bovis BCG Pasteur, but pre-
sent in BCG Moreau [6,7].
The low levels of MPB70 and MPB83 in M. bovis
BCG Pasteur were also confirmed in our study. Their
reduced expression is due to a point mutation in the
translational start codon of the sigK gene [67], observed
in many BCG strains, but absent in BCG Moreau.
Immunologic studies have shown that both proteins
induce cellular and humoral immune responses in
experimental models of infection and in natural infec-
tion in humans [68,69]. MPB63 is a protein only found
in species within the Mtb complex [70], shown to be
immunodominant both in humans and animal models
[71] and a promising candidate for serodiagnosis of
active TB as well as for vaccine development. MPB63
was identified in four different spots (109,111,112 and
160), 2 of which (111 and 160) showed statistically sig-
nificant differences in expression, with an increase of
more than 3-fold in BCG Moreau as compared to BCG
Pasteur (Table 1 and Figure 5). These 4 protein spots
are likely to represent isoforms, probably differing due
to the presence of PTMs, known to cause changes in pI
resulting in slightly different migration. Moreover,
MPB63 contains an N-terminal signal sequence as pre-
dicted by the SignalP software, which was experimen-
tally verified [72].
The alanine-proline rich protein (Apa, Rv1860,
BCG1896, spots 11, 12, 13 and 14) is known to present
a high content of proline and carbohydrate groups [37]
that interferes with its migratory behavior in SDS-
PAGE. Although we have not identified modifications
such as glycosylation, this protein displays a characteris-
tic four-spot pattern (doublet of 2 horizontally dispersed
spots) on 2DE [39] (Additional file 5, Figure S2). The
isoforms of lowest molecular mass (spots 13 and 14)
showed a statistically significant 3-fold increase in
expression in BCG Moreau (Table 1 and Figure 5). This
protein seems to be restricted to the Mtb complex and
has been shown to be a target for immune recognition
in animals immunized with live BCG [73]. In addition
to its high immunogenicity, it has also been described as
a potential adhesin involved in the colonization of target
cells [39]. Its higher expression could contribute to an
increase in the immunogenicity of BCG Moreau.
Four proteins were found to be at least 2-fold more
expressed in BCG Pasteur compared to Moreau: a pepti-
dyl-prolyl cis-trans isomerase (PPIaseA, Rv0009,
BCG0009), the trigger factor (TF, Rv2462c, BCG2482c),
Hsp65 (GroEL2, Rv0440, BCG0479) and Hsp70 (DnaK,
Rv0350, BCG0389), all described as participating in pro-
tein folding and response to stress, among other func-
tions. The gene ppiA is located in the Pasteur-specific
DU1 duplicated region. The duplication of this gene
alone may be responsible for the observed increased
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expression of PPIaseA in BCG Pasteur. Comparative
transcriptome analysis has shown that bcg0009, bcg0389,
bcg0479 and bcg2482c are all up-regulated in BCG Pas-
teur when compared to BCG Tokyo [11]. Considering
the genealogy of BCG vaccines [7], BCG Moreau, Tokyo
and Russia belong to the same group of “older” strains,
closer to the original attenuated strain derived by Calm-
ette and Guérin in the early 1920’s, and all lack the
DU1 duplication. The genome of BCG Pasteur, unlike
the older strains, carries 2 copies of sigH, due to a sec-
ond genomic duplication (DU2), and its expression is at
least 2-fold higher [11]. SigH is an alternative extra-
cytoplasmic sigma factor involved in the response to
heat shock and oxidative stress, positively regulating the
expression of other genes, including dnaK and possibly
groEL2 [74]. GroEL2 (Rv0440, BCG0479; Hsp65) and
DnaK (Rv0350, BCG0389; Hsp70) are chaperones
involved in protein-folding, and have been associated
with the induction of protection against TB infection in
mice by immunization with experimental DNA vaccines
[75,76]. Recently, these mycobacterial chaperones have
been described as having vital moonlighting functions
when present outside the cell: GroEL2 acts as a major
adhesin, mediating binding of Mtb to monocytes and
the soluble protein is capable of competing for this
binding, reducing bacterial association to macrophages
[77]. DnaK stimulates the secretion of chemokines
required for granuloma formation [78] and its overex-
pression was found to favor the host over the pathogen
during chronic Mtb infection [79]. All in all, subtle var-
iations in the balance of expression and/or localization
of these proteins may have profound impacts on the
interaction between the bacteria (in this case, different
BCG vaccine strains) and the host’s immune system,
impacting vaccine efficacy.
Conclusions
The findings reported here provide new information
about the proteomic characteristics of the BCG Moreau
vaccine strain and contribute to shed more light on the
differentiated immune response and the variable effec-
tiveness of the different BCG vaccines. In Brazil,
approximately 90,000 new cases of TB are reported
annually by the health system [80]. The BCG Moreau
vaccine has been used since 1925, and its production by
Fundação Ataulpho de Paiva (FAP) currently represents
5% of the BCG vaccine production in the world [10].
According to recent data from the WHO, global BCG
immunization increased since the 1980’s and Brazil,
with a population close to 200 million, shows over 99%
coverage for BCG vaccination [81]. Despite the genetic
differences accumulated in BCG strains, the originally
described protective efficacy of BCG Moreau was not
reduced, and the Brazilian strain is regarded as one of
the most immunogenic among the vaccine preparations
that are currently available [82,83]. The exploration of
the secreted sub-proteome of M. bovis BCG Moreau
provides valuable information regarding specific pro-
teins, many of which have been implicated in protective
immune responses, and helps defining candidates for
future vaccination strategies.
Methods
Bacterial strains and growth conditions
Mycobacterium bovis BCG Pasteur 1173P2 was obtained
from the Pasteur Institute (Paris, France) culture collec-
tion, and stocks were maintained at -80°C. Mycobacter-
ium bovis BCG Moreau was provided by Fundação
Ataulpho de Paiva (FAP). Both strains were cultured as
surface pellicles, for 2 weeks at 37°C, in 100 ml of Sau-
ton vaccine production medium, provided by FAP.
Sample preparation
Culture filtrate proteins (CFPs) were obtained after
separation of culture supernatants from the bacterial
pellicles and subsequent centrifugation at 2,500 × g for
10 min at 4°C. The resulting supernatant was filtered
through a 0.22 μm low protein binding membrane
(Millipore Express; Millipore, Bedford, MA, USA) in
order to remove any remaining bacteria. CFPs (on aver-
age 5.5 mg total protein) were precipitated with 17% (v/
v) TCA and washed with cold acetone. Finally, proteins
were dissolved in 1.5 ml of IEF buffer (8 M urea, 2%
CHAPS, 4 mM tributylphosphine [TBP], 0.4% ampho-
lytes pH 3-10) for 1 h at room temperature. Protein
concentration was determined using the RC-DC Kit
(Bio-Rad). Proteins were stored at -80°C until analysis.
Two dimensional gel electrophoresis (2DE)
IPG strips and all 2DE reagents were purchased from
Bio-Rad (Hercules, CA, USA). Isoelectric focusing was
performed at 20°C on 17 cm IPG strips, using 500 μg of
CFPs diluted in a final volume of 300 μl in rehydration
buffer (8 M urea, 2% CHAPS, 4 mM TBP, 0.4% ampho-
lytes pH 3-10). Samples were applied to IPG strips (pH
intervals of 3-6, 4-7 and 5-8) by in-gel rehydration and
incubated for 1 h at room temperature. Isoelectric
focusing was performed on a Protean® IEF cell (Bio-
Rad) with maximum current of 50 μA/strip. Focusing
parameters used for IPG strips in the pH range 4-7 and
5-8 were: active rehydration (50 V) for 11 h; step 1- lin-
ear gradient from 1 to 250 V over 20 min; step 2 - lin-
ear gradient from 250 to 10,000 V over 2 h; step 3-
constant 10,000 V until 80,000 Vh was achieved. For
IPG strips in the pH range 3-6, step 3 was constant
10,000 V until 60,000 Vh was achieved. After isoelectric
focusing, proteins were reduced in 130 mM DTT and
alkylated in 270 mM iodoacetamide, both in
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equilibration buffer (6 M urea, 2% SDS, 375 mM Tris-
HCl pH 8.8, 20% glycerol). Second dimension separation
was done in 17 cm, 12% or 15% SDS-PAGE gels, 1.0
mm thick, using a vertical system (Bio-Rad) in standard
Laemli buffer [84] at 40 mA/gel, 10°C, until the tracking
dye left the gel.
Protein visualization and image analysis
Gels were stained with colloidal Coomassie Brilliant
Blue G-250 essentially as described [85], and documen-
ted using a GS-800™ auto-calibrating imaging densit-
ometer (Bio-Rad). Image analysis was performed using
PDQuest™ software version 8.0.1 (Bio-Rad). Compara-
tive 2DE data were derived from 4 separate protein pre-
parations, each one obtained from independent cultures.
The spots were quantified on the basis of their relative
‘volume’: the amount of a protein spot was expressed as
the sum of the intensities of all the pixels that made up
the spot. To compensate for subtle differences in sample
loading, gel staining and de-staining, the volume of each
spot was normalized in relation to the total density of
valid spots present in the gel image. After automated
detection and matching, manual editing was carried out.
To determine the experimental pI and Mr coordinates
for each single protein spot, 2DE gels were calibrated
using a selected set of five protein landmarks distributed
throughout the gel.
Protein digestion, peptide extraction and MS/MS analysis
In-gel digestion of 2DE separated protein spots was car-
ried out essentially as described [86]. Briefly, protein
spots were excised and the gel pieces washed 3 times
with 50% (v/v) acetonitrile (ACN) in 25 mM ammonium
bicarbonate for 15 min each, dehydrated in ACN, and
dried in a vacuum centrifuge. Gel pieces were rehy-
drated in 15 μl of 50 mM ammonium bicarbonate con-
taining 200 ng of sequencing grade modified trypsin
(Promega). This step was performed for 40 minutes at
4°C and, after that, 20 μl of 50 mM ammonium bicarbo-
nate were added to keep the gel pieces wet during tryp-
tic digestion (37°C, 16 h). To extract peptides, 20 μl of
0.5% (v/v) trifluoroacetic acid (TFA) in 50% (v/v) ACN
were added and samples were sonicated 3 times for 10
min each in a sonicator bath. The supernatant was
recovered and concentrated under vacuum to a volume
of approximately 10 μl. The resulting peptides were
extracted, partially dried, and salts were removed using
C18 ZipPlate (Millipore, Bedford, MA) following the
manufacturer’s instructions.
The tryptic peptides were analyzed in a 4700-Proteo-
mics Analyzer MALDI-TOF/TOF (Applied Biosystems,
Foster City, CA). All mass spectra were acquired on
positive ion reflector mode with 2,000 shots per spot
and externally mass calibrated with a peptide mixture.
The 10 most intense ion peaks from the peptide mass
fingerprinting (or MS run) were further submitted to
fragmentation using PSD mode with CID gas off and 1
keV collision energy.
Protein identification
Following MS acquisition, each spectrum was submitted
to a peptide mass fingerprinting search, in the case of MS/
MS spectra, using Mascot version 2.2 (Matrix Science -
http://www.matrixscience.com/ ). For protein identifica-
tion, the search was performed against the NCBI-nr non-
redundant database (NCBI-nr200709, National Center for
Biotechnology Information, http://www.ncbi.nlm.nih.gov/)
without taxonomy restriction. When necessary, further
searches were performed against the Mycobacterium
tuberculosis database (http://genolist.pasteur.fr/tubercu-
list). Decoy search was performed automatically on the
search form from Mascot using the same database
described above with taxonomy restriction to the Myco-
bacterium tuberculosis complex to determine the false dis-
covery rate (FDR). A FDR < 3.0% to peptide matches
above homology or identity threshold was considered sig-
nificant. For Mascot searches, the parameters used were
trypsin as the enzyme of choice and one missed cleavage,
± 1 Da for the precursor mass, ± 0.5 Da for the fragment
ion mass. Oxidation of methionines along with N-terminal
acetylation of proteins, N-terminal formylation, deamida-
tion and cyclization of glutamine (pyro-glutamate) were
allowed as possible modifications whereas alkylation of
cysteines (carbamidomethylcysteines) was set as constant
modification. Identification was considered valid for Mas-
cot protein scores greater than 30 and a significance
threshold of p < 0.05. If a protein ‘hit’ was identified by
only one peptide, the MS/MS data was to exhibit a clear
spectrum with sequence tags that matched at least three
consecutive y or b fragment ion series. Finally, a good cor-
relation between the experimental and theoretical molecu-
lar mass and pI was also considered for positive
identifications.
Putative signals for protein export were predicted
using SignalP 3.0 (http://www.cbs.dtu.dk/services/Sig-
nalP/), LipoP 1.0 (http://www.cbs.dtu.dk/services/
LipoP/), TatP 1.0 (http://www.cbs.dtu.dk/services/TatP/)
and SecretomeP 2.0 (http://www.cbs.dtu.dk/services/
SecretomeP/). Potential transmembrane domais were
predicted with TMHMM 2.0 (http://www.cbs.dtu.dk/ser-
vices/TMHMM/).
Molecular weight (Mr) and pI of secreted proteins was
calculated with the Expasy compute pI/Mw tool (http://
www.expasy.ch/tools/pi_tool.html).
Statistical analysis
Spot intensity differences obtained from comparative
2DE gel images of M. bovis BCG strains Moreau and
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Pasteur were statistically analyzed by one-way ANOVA
with Student’s t-test to determine significant differences
among group means. Statistical analysis was carried out
using the data obtained from 4 different sets of indepen-
dent biological samples. A p-value ≤0.05 was considered
as statistically significant.
Additional material
Additional file 1: Figure S1 - PCR confirmation of the genetic
identity of the BCG strains used.
Additional file 2: Table S1 - M. bovis BCG Moreau culture filtrate
proteins identified by MS/MS
Additional file 3: Table S2 - Predicted localization of identified
proteins.
Additional file 4: Table S3 - Mr and pI of secreted proteins.
Additional file 5: Figure S2 - Magnified 2DE gel regions showing
protein spots differentially expressed between BCG strains Moreau
and Pasteur. Panels A - F represent the magnified gel regions indicated
in Figure 4. Protein spot numbering is the same as in Figure 1.
Additional file 6: Figure S3 - Magnified 2DE gel regions showing
protein spots expressed exclusively in BCG strains Moreau or
Pasteur. Panels A and B represent the magnified gel regions as
indicated in Figure 4. Protein spot numbering is the same as in Figure 1.
MPT64 (spots 69 and 158) and CFP21 (spot 96) are only found in BCG
Moreau culture filtrate (panel A), while Rv3400 (BCG3470) was only found
in BCG Pasteur (panel B).
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